Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab in Patients With Inclusion Body Myositis
NCT00079768Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Mar 2004
- Primary completion
- Mar 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in inclusion body myositis (IBM), sponsored by National Institute of Neurological Disorders and Stroke. Started Mar 2004; status: completed.
02
Drugs
alemtuzumab
03
Conditions
inclusion body myositis (IBM)
Beyond the preview
Go deeper on NCT00079768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00079768.